plasma cell disorders
Conditions
Interventions
newly diagnosed plasma cell disorder group:treatment regimen based on bortezomib
relapsed and/or refractory plasma cell disorder group:treatment regimen based on bortezomib
control group (early stages of plasma cell disorders):treatment regimen based on bortezomib
Sponsors
Department of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China
Eligibility
Sex/Gender
All
Age
18 Years to 95 Years
Inclusion criteria
Inclusion criteria: Patients must meet the following inclusion criteria to be eligible for this clinical study: 1. Know and voluntarily sign the Informed Consent Form (ICF). 2. Age= 18 years old. 3. Diagnosed plasma cell disorders (meeting diagnostic criteria for different plasma cell disorders): A. Diagnostic criteria for multiple myeloma, smoldering multiple myeloma, monoclonal gammopathy of undetermined significance, and solitary plasmacytoma, refer to 2014 Lancet Oncol (Rajkumar et al., 2014); B. Diagnostic criteria for amyloidosis, refer to 2022 Am J Hematol (Gertz, 2022); C. Diagnostic criteria for macroglobulinemia, refer to 2023 Am J Hematol (Gertz, 2023); D. Diagnostic criteria for POEMS syndrome, refer to 2021 Am J Hematol (Dispenzieri, 2021); E. Other plasma cell disorders. 4. Life expectancy is more than 3 months.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following exclusion criteria are not enrolled: 1. Pregnancy or lactation. 2. History of alcoholism, drug addiction and mental illness. 3. Other circumstances deemed by the investigator to be unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Multi-omics data; | — |
Secondary
| Measure | Time frame |
|---|---|
| Analysis of clinical characteristics; | — |
Countries
China
Contacts
Public ContactJuan Du
Department of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China
Outcome results
None listed